---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-009982"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:54:03.279762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monopar Therapeutics reports Q4 2024 net loss $10.9M; cash $60.2M; ALXN1840 NDA planned early 2026

## Summary
- Q4 2024 net loss $10.9M ($2.23/share) vs $1.8M ($0.60/share) in Q4 2023.
- FY2024 net loss $15.6M ($4.11/share) vs $8.4M ($3.04/share) in FY2023; R&D expenses rose to $13.0M from $5.6M.
- Cash and short-term investments $60.2M at Dec 31, 2024; expects runway through Dec 31, 2026.
- Plan to submit NDA for ALXN1840 (Wilson disease) to FDA in early 2026.
- Raised net proceeds ~$55M from Q4 2024 financings; MNPR-101-Lu Phase 1a dosed first patient in December 2024.

## SEC filing metadata
- accession: 0001437749-25-009982
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/0001437749-25-009982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/mnpr20250326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-009982
- JSON: https://secwatch.observer/filing/0001437749-25-009982.json
- Plain text: https://secwatch.observer/filing/0001437749-25-009982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.